The 5-hydroxytryptamine receptor 6 (5-HT6) has gained attention as a target for developing therapeutics for Alzheimer’s disease, schizophrenia, cognitive dysfunctions, anxiety, and depression, to list a few. Here, HTR6 is linked to major depressive disorder.